Valuation
- Market cap
- —
- Revenue TTM
- $0
- Net income TTM
- $0
- PE ratio
- —
- Forward PE
- —
- Profit margin
- 0.00%
- Debt to equity
- —
Trading
- Volume
- 2,000
- Avg volume
- 34,998
- Day's range
- $0.00 – $0.00
- Shares out
- —
- Stochastic %K
- 0%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- —
Company profile
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its n...
Show more
MabCure, Inc., a development stage company, engages in developing and commercializing its proprietary antibody technology for the early detection of cancer, and for the creation of specific therapeutics against cancer. It owns a proprietary technology for the generation of monoclonal antibodies against desired antigens, such as cancer markers. The company was formerly known as Smartec Holdings, Inc. and changed its name to MabCure, Inc. in January 2008 to reflect its new business plan. MabCure, Inc. was founded in 2006 and is based in White Plains, New York.
- Industry
- Solar
- Sector
- Technology
- Phone
- 845 591 3144
- Address
- 21 Sparrow Circle, White Plains, United States
Latest news
No headlines yet.
